Antioxidant and Lysosomotropic Properties of Acute d-Propranolol Underlies Its Cardioprotection of Postischemic Hearts from Moderate Iron-Overloaded Rats
Restricted accessResearch articleFirst published online April, 2006
Antioxidant and Lysosomotropic Properties of Acute d-Propranolol Underlies Its Cardioprotection of Postischemic Hearts from Moderate Iron-Overloaded Rats
The benefits of acute d-propranolol (d-Pro, non–β-adrenergic receptor blocker) pretreatment against enhanced ischemia/reperfusion (I/R) injury of hearts from moderate iron-overloaded rats were examined. Perfused hearts from iron-dextran-treated rats (450 mg/kg/week for 3 weeks, intraperitoneal administration) exhibited normal control function, despite iron treatment that elevated plasma iron and conjugated diene levels by 8.1-and 2.5-fold, respectively. However, these hearts were more susceptible to 25 mins of global I/R stress compared with nonloaded hearts; the coronary flow rate, aortic output, cardiac work, left ventricular systolic pressure, positive differential left ventricular pressure (dP/dt), and left ventricular developed pressure displayed 38%, 60%, 55%, 13%, 41%, and 15% lower recoveries, respectively, and a 6.5-fold increase in left ventricular end-diastolic pressure. Postischemic hearts from iron-loaded rats also exhibited 5.6-, 3.48-, 2.43-, and 3.45-fold increases in total effluent iron content, conjugated diene levels, lactate dehydrogenase (LDH) activity, and lysosomal N-acetyl-β-glucosaminidase (NAGA) activity, respectively, compared with similarly stressed nonloaded hearts. A comparison of detection time profiles during reperfusion suggests that most of the oxidative injury (conjugated diene) in hearts from iron-loaded rats occurred at later times of reperfusion (8.5-15 mins), and this corresponded with heightened tissue iron and NAGA release, d-Pro (2 μM infused for 30 mins) pretreatment before ischemia protected all parameters compared with the untreated iron-loaded group; pressure indices improved 1.2- to 1.6-fold, flow parameters improved 1.70- to 2.96-fold, cardiac work improved 2.87-fold, and end-diastolic pressure was reduced 56%. d-Pro lowered total release of tissue iron, conjugated diene content, LDH activity, and NAGA activity 4.59-, 2.55-, 3.04-, and 4.14-fold, respectively, in the effluent of l/R hearts from the iron-loaded group. These findings suggest that the enhanced postischemic dysfunction and tissue injury of hearts from iron-loaded rats was caused by excessive iron-catalyzed free radical stress, and that the membrane antioxidant properties of d-Pro and its stabilization of sequestered lysosomal iron by d-Pro may contribute to the cardioprotective actions of d-Pro.
GiardinaPJ, GradyRW. Chelation therapy in beta-thalassemia: the benefits and limitations of desferrioxamine. Semin Hematol32: 304–312, 1995.
2.
HershkoC, LinkG, CabantchikI. Pathophysiology of iron overload. Ann N Y Acad Sci850: 191–201, 1998.
3.
MasiniA, TrentiT, CeccarelliD, MuscatelloU. Mitochondrial involvement in causing cell injury in experimental hepatic iron overload. Ann N Y Acad Sci488: 517–519, 1986.
4.
GuntherT, HollrieglV, VormannJ, DischG, ClassenHG. Effects of Fe loading on vitamin E and malondialdehyde of liver, heart and kidney from rats fed diets containing various amounts of magnesium and vitamin E. Magnesium-Bulletin14: 88–93, 1992.
5.
PepperJR, MumbyS, GutteridgeJM. Blood cardioplegia increases plasma iron overload and thiol levels during cardiopulmonary bypass. Ann Thorac Surg60: 1735–1740, 1995.
6.
MariottiE, AngelucciE, AgostiniA, BaroncianiD, SgarbiE, LucarelliG. Evaluation of cardiac status in iron-loaded thalassaemia patients following bone marrow transplantation: improvement in cardiac function during reduction in body iron burden. Br J Haematol103: 916–921, 1998.
7.
JensenPD, OlsenN, BaggerJP, JensenFT, ChristensenT, EllegaardJ. Cardiac function during iron chelation therapy in adult non-thalassaemic patients with transfusional iron overload. Eur J Haematol59: 221–230, 1997.
8.
LombardoT, TamburinoC, BartoloniG, MorroneML, FrontiniV, ItaliaF, CordaroS, PriviteraA, CalviV. Cardiac iron overload in thalassemic patients: an endomyocardial biopsy study. Ann Hematol71: 135–141, 1995.
9.
PolitiA, SticcaM, GalliM. Reversal of haemochromatotic cardiomyopathy in beta thalassaemia by chelation therapy. Br Heart J73: 486–487, 1995.
10.
KremastinosDT, TiniakosG, TheodorakisGN, KatritsisDG, ToutouzasPK. Myocarditis in beta-thalassemia major. A cause of heart failure. Circ91: 66–71, 1995.
11.
WhittakerP, HinesFA, RoblMG, DunkelVC. Histopathological evaluation of liver, pancreas, spleen, and heart from iron-overloaded Sprague-Dawley rats. Toxicol Pathol24: 558–563, 1996.
12.
BrunA, BrunkU. Histochemical indications for lysosomal localization of heavy metals in normal rat brain and liver. J Histochem Cytochem18: 820–827, 1970.
13.
van der SchouwYT, van der VeekenPMWC, KokFJ, KosterJF, SchoutenEG, HofmanA. Iron status in the acute phase and six weeks after myocardial infarction. Free Rad Biol Med8: 47–53, 1990.
14.
AustSD, WhiteBC. Iron chelation prevents tissue injury following ischemia. Free Rad Biol Med1: 1–17, 1985.
15.
van der KraaijAMM, MostertL, van EijkHG, KosterJF. Iron-load increases the susceptibility of rat hearts to oxygen reperfusion damage. Protection by the antioxidant (+)-cyanidanol-3 and deferoxamine. Circ78: 442–449. 1988.
16.
VoogdA, SluiterW, van EijkHG, KosterJF. Low molecular weight iron and the oxygen paradox in isolated rat hearts. J Clin Invest90: 2050–2055, 1992.
BiemondP, van EijkHG, SwaakAJ, KosterJF. Iron mobilization from ferritin by superoxide derived from stimulated polymorphonuclear leukocytes. Possible mechanism in inflammation diseases. J Clin Invest73: 1576–1579, 1984.
19.
PrasadMR, EngelmanRM, JonesRM, DasDK. Effect of oxyradicals on oxymyoglobin. Deoxygenation, haem removal and iron release. Biochem J263: 731–736, 1989.
20.
KosterJF, VoogdA, RuigrokTJ, SluiterW. Depletion of preischemic glycogen reduces the increase of low molecular weight iron during ischemia. Ann N Y Acad Sci793: 74–84, 1996.
21.
HershkoC, LinkG, CabantchikI. Pathophysiology of iron overload. Ann N Y Acad Sci850: 191–201, 1998.
22.
EatonJW, QianM. Molecular bases of cellular iron toxicity. Free Rad Biol Med32: 833–840, 2002.
23.
WhittakerP, WarnerWG, ChanderbhanRF, DunkelVC. Effects of alpha-tocopherol and beta-carotene on hepatic lipid peroxidation and blood lipids in rats with dietary iron overload. Nutr Cancer25: 119–128, 1996.
24.
BartfayWJ, HouD, BrittenhamGM, BartfayE, SoleMJ, LehotayD, LiuPP. The synergistic effects of vitamin E and selenium in iron-overloaded mouse hearts. Can J Cardiol14: 937–941, 1998.
25.
MakIT, WeglickiWB. Protection by beta-blocking agents against free radical-mediated sarcolemmal lipid peroxidation. Circ Res63: 262–266, 1988.
26.
MakIT, ArroyoCM, WeglickiWB. Inhibition of sarcolemmal carbon-centered free radical formation by Propranolol. Circ Res65: 1151–1156, 1989.
27.
MakIT, KramerJH, FreedmanAM, TseSYH, WeglickiWB. Oxygen free radical-mediated injury of myocytes-protection by Pro. J Mol Cell Cardiol22: 687–695, 1990.
28.
WeglickiWB, MakIT, DickensBF, KramerJH. Beta-blockers, calcium channel blockers and the sulfhydryl-ACE inhibitors demonstrate protection against free radical-mediated injury of cardiovascular cells and membranes. Rev Port Cardiol11: 1009–1011, 1992.
29.
KramerJH, MakIT, FreedmanAM, WeglickiWB. Propranolol reduces anoxia/reoxygenation-mediated injury of adult myocytes through an anti-radical mechanism. J Mol Cell Cardiol23: 1231–1244, 1991.
30.
KramerJH, MisikV, WeglickiWB. Lipid peroxidation-derived free radical production and post-ischemic myocardial reperfusion injury. Ann N Y Acad Sci723: 180–196, 1994.
31.
CrambG. Selective lysosomal uptake and accumulation of the beta-adrenergic antagonist propranolol in cultured and isolated cell systems. Biochem Pharmacol35: 1365–1372. 1986.
32.
YuZ, PerssonHL, EatonJW, BrunkUT. Intralysosomal iron: a major determinant of oxidant-induced cell death. Free Rad Biol Med34: 1243–1252, 2003.
33.
YangT, BrittenhamGM, DongWQ, LevyMN, Obejero-PazCA, KuryshevYA, BrownAM. Deferoxamine prevents cardiac hypertrophy and failure in the gerbil model of iron-induced cardiomyopathy. J Lab Clin Med142: 332–340, 2003.
34.
OuditGY, TrivieriMG, KhaperN, HusainT, WilsonGJ, LiuP, SoleMJ, BackxPH. Taurine supplementation reduces oxidative stress and improves cardiovascular function in an iron-overload murine model. Circ109: 1877–1885, 2004.
35.
Obejero-PazCA, YangT, DongWQ, LevyMN, BrittenhamGM, KuryshevYA, BrownAM. Deferoxamine promotes survival and prevents electrocardiographic abnormalities in the gerbil model of iron-overload cardiomyopathy. J Lab Clin Med141: 121–130, 2003.
36.
BartfayWJ, BartfayE. Iron-overload cardiomyopathy: evidence for a free radical-mediated mechanism of injury and dysfunction in a murine model. Biol Res Nurs2: 49–59, 2000.
37.
KramerJH, MisikV, WeglickiWB. Magnesium-deficiency potentiates free radical production associated with post-ischemic injury to rat hearts: vitamin E affords protection. Free Rad Biol Med16: 713–723, 1994.
MurthiSB, KramerJH, WiseRM, MakIT, ChmielinskaJ, WeglickiWB. Chronic d-Pro treatment reduces iron-overload-mediated systemic injury and loss of rat heart function (abstract). FASEB J17: A1163, 2003.
42.
PucheuS, CoudrayC, TresalletN, FavierA, de LeirisJ. Effect of iron overload in the isolated ischemic and reperfused rat heart. Cardiovasc Drugs Ther7: 701–711, 1993.
43.
CoudrayC, PucheuS, BoucherF, ArnaudJ, de LeirisJ, FavierA. Effect of ischemia/reperfusion sequence on cytosolic iron status and its release in the coronary effluent in isolated rat hearts. Biol Trace Elem Res41: 69–75, 1994.
44.
KramerJH, LightfootF, WeglickiWB. Cardiac tissue iron: effects on postischemic function and free radical production, and its possible role during preconditioning. Cell Mol Biol46: 1313–1327, 2000.
45.
ChevionM, LiangY, Har-ElR, BerenshteinE, UretzkyG, KitrosskyN. Copper and iron are mobilized following myocardial ischemia: possible predictive criteria for tissue injury. Proc Natl Acad Sci U S A90: 1102–1106, 1993.
46.
OpieLH. Myocardial ischemia—metabolic pathways and implications of increased glycolysis. Cardiovasc Drugs Ther4: 777–790, 1990.
47.
SchafferSW, SaferB, FordC, IllingworthJ, WilliamsonJR. Respiratory acidosis and its reversibility in perfused rat heart: regulation of citric acid cycle activity. Am J Physiol234: H40–H51, 1978.
48.
LevineRL. Ischemia: from acidosis to oxidation. FASEB J7: 1242–1246, 1993.
49.
DeckerRS, PooleAR, GriffinEE, DingleJT, WildenthalK. Altered distribution of lysosomal cathepsin D in ischemic myocardium. J Clin Invest59: 911–921, 1977.
50.
MairJ. Tissue release of cardiac markers: from physiology to clinical applications. Clin Chem Lab Med37: 1077–1084, 1999.
51.
LesnefskyEJ. Tissue iron overload and mechanisms of iron-catalyzed oxidative injury. Adv Exp Med Biol366: 129–146, 1994.
52.
BoucherF, PucheuS, CoudrayC, FavierA, de LeirisJ. Evidence of cytosolic iron release during post-ischaemic reperfusion of isolated rat hearts: influence on spin-trapping experiments with DMPO. FEBS Lett302: 261–264, 1992.
53.
ArroyoCM, KramerJH, DickensBF, WeglickiWB. Identification of free radicals in myocardial ischemia/ reperfusion by spin trapping with nitrone DMPO. FEBS Lett221: 101–104, 1987.
54.
ArroyoCM, KramerJH, LeiboffRH, MergnerGW, DickensBF, WeglickiWB. Spin trapping of oxygen and carbon-centered free radicals in ischemic canine myocardium. Free Rad Biol Med3: 313–316, 1987.
55.
WeglickiWB, ArroyoCM, KramerJH, MakIT, LeiboffRH, MergnerGW, DickensBF. Applications of spin trapping/ESR techniques in models of cardiovascular injury. In: CeruttiPA, FridovichI, McCordJM, Eds. Oxy-Radicals in Molecular Biology and Pathology. New York:Alan R Liss, pp 357–364, 1988.
56.
CobbeSM, Poole-WilsonPA. The time of onset and severity of acidosis in myocardial ischaemia. J Mol Cell Cardiol12: 745–760, 1980.
57.
WeglickiWB, MakIT, DickensBF, StaffordRE, KomarovAM, GibsonB, CassidyMM, PhillipsTM, KramerJH. Neuropeptides, free radical stress and antioxidants in models of Mg-deficient cardiomyopathy. In: TheophanidesT, AnastassopoulouJ, Eds. Magnesium: Current Status and New Developments. Dordrecht, the Netherlands:Kluwer Academic Publishers, pp 169–178, 1997.
58.
DickensBF, WeglickiWB, BoehmePA, MakIT. Antioxidant and lysosomotropic properties of acridine Propranolol: protection against oxidative endothelial cell injury. J Mol Cell Cardiol34: 129–137, 2002.
